Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 33.32 as of 2026-10-06T19:23:51.193Z.
Consensus retrieved: 2026-10-06T16:18:32.340Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:23:51.193Z.
Quote observation: 2026-10-06T19:20:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5ca4feafebbf69fab89f600f241eff8316bc361f0cd7295f04f28d0809a33ca7
Forward PE Ratio (33.32) = Dated Quote Price ($13.56) / Consensus Forward EPS ($0.41)
FORWARD PE RATIO
33.32
SECTOR MEDIAN · HEALTHCARE
19.87
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+67.69%
vs the sector median at left
Surgery Partners, Inc.
Market Cap
$1.77B
Forward PE Ratio
33.32
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Surgery Partners, Inc. (SGRY) | $1.77B | 33.32 |
| Absci Corporation (ABSI)vs › | $1.76B | N/A |
| Xencor, Inc. (XNCR)vs › | $1.79B | N/A |
| Generate Biomedicines, Inc. (GENB)vs › | $1.79B | N/A |
| Novocure Ltd (NVCR)vs › | $1.75B | N/A |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.81B | 5.34 |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 27.63 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | N/A |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.73B | N/A |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.72B | 45.80 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
33.3
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $13.56, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.41 | $0.26 – $0.48 | 3 | 33.3x |
| 2027-12-31 | $0.43 | $0.32 – $0.55 | 3 | 31.5x |
| 2028-12-31 | $0.62 | $0.61 – $0.63 | 1 | 21.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
